Evidence map›Paper›PMID 40447311›Full record

ArticleJournal of medical genetics2025

Using long-read sequencing to detect and subtype a case with Temple syndrome.

Sarah Dada, Vahid Akbari, Duha Hejla, Yaoqing Shen, Katherine Dixon, Sanaa Choufani, Rosanna A Weksberg, Cornelius F Boerkoel, Laura Stewart, Kamilla Schlade-Bartusiak and 5 more

Abstract readCase Reports
In one paragraph

Article in Journal of medical genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Sarah Dada *Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-3445-2377
Vahid Akbari *Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0001-8005-7776
Duha HejlaBC Children's Hospital, Vancouver, British Columbia, Canada.
Yaoqing ShenCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
Katherine DixonCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada.
Sanaa ChoufaniProgram in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Rosanna A WeksbergProgram in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Cornelius F BoerkoelDepartment of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Laura StewartBC Children's Hospital, Vancouver, British Columbia, Canada.
Kamilla Schlade-BartusiakDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Emma StrongDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Danya FoxBC Children's Hospital, Vancouver, British Columbia, Canada.
Daniel GamuDepartment of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
William T GibsonDepartment of Medical Genetics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID http://orcid.org/0000-0002-6552-402X
Steven J M JonesCanada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, British Columbia, Canada sjones@bcgsc.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Temple syndrome is an imprinting disorder resulting from abnormal genomic or epigenomic aberrations of chromosome 14 including maternal uniparental disomy (matUPD), paternal deletion of 14q32, or aberrant methylation of the imprinting control regions at 14q32. Understanding the underlying molecular mechanism is essential to understanding the recurrence risk and physical effects. Currently, diagnosis requires the detection of aberrant methylation and copy number loss via methylation-sensitive assays such as methylation-specific multiplex ligation-dependent probe amplification, and short tandem repeat analysis to detect matUPD and the presence of epimutation. Therefore, a one-step approach that can detect aberrant methylation and underlying genetic mechanisms would be of high clinical value. Here we use nanopore sequencing to delineate the molecular diagnosis of a case with Temple syndrome. We demonstrate the application of nanopore sequencing to detect aberrant methylation and underlying genetic mechanisms simultaneously in this case, thus providing a proof of concept for a one-step approach for molecular diagnosis of this disorder.

Indexed as

Uniparental DisomyChromosomes, Human, Pair 14DNA MethylationFaciesGenomic ImprintingHigh-Throughput Nucleotide SequencingHumansImprinting DisordersMuscle HypotoniaNanopore SequencingDNA MethylationEpigenomicsGenetics, MedicalGenomicsNanopore Sequencing

Identifiers

PMID40447311
PMCPMC12322394

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.